Abstract 4503
Background
NAVYA is a validated online cancer informatics solution that combines artificial intelligence (AI) and rapid review (2 mins/case) by multi-disciplinary tumor board experts at Academic Medical Centers (AMC) to deliver multidisciplinary expert treatment plan to patients within 24 hours. Initially developed for patients in India without ready access to expertise, over 28,000 patients across 68 countries have since reached out to NAVYA. Prior research (SABCS and ASCO 2014-2018) showed, 1) 97% concordance of NAVYA with an AMC in India and in the US 2) 97% of patients experienced significant anxiety relief due to 24 hours turnaround time. NAVYA scales access to expertise unlike the limitations of synchronized 1 patient: 1 doctor consults in telemedicine.
Methods
Three patient centered outcomes (travel distance, cost and time to receive expert treatment plan) were studied. All consecutive patients who reached out to NAVYA between 1/1/17-1/31/19 but ultimately opted for in-person visit to an AMC were contacted by prospective phone follow up. This was compared to a numerically balanced random sample of patients who only used NAVYA to obtain treatment plans.
Results
Prospective phone follow-ups with 902 in-person patients and 901 NAVYA patients were analyzed. The groups did not differ significantly in demographics or disease characteristics. In-person patients and NAVYA patients differed significantly with respect to 1) median travel distance (761 miles, IQR (152 -1083 miles) vs. 0 miles (p < 0.05)) 2) travel related costs of $1250 [95% CI +/- $54.5] vs $105 online processing fee 3) total time to receipt of treatment plan (4.66 days, IQR (0.4 - 20.3 days) vs. 1.04 day IQR (0.4-2.5) (p < 0.05)).
Conclusions
Cancer informatics solutions that combine AI with human clinical expertise to generate multidisciplinary treatment plans tailored to an individual patient, and vetted by experts at AMC, scale ready access to expertise around the world. For patients with limited access to AMC, such solutions eliminate travel burden, and significantly reduce cost and wait time. This has significant implications for creating access to specialty expertise, globally.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3611 - Phase II trial of SM 88 in Non-Metastatic Biochemical Recurrent Prostate Cancer.
Presenter: Benjamin Gartrell
Session: Poster Display session 3
Resources:
Abstract
2492 - A phase 1 study of Ad5 PSA/MUC-1/Brachyury Vaccine in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC)
Presenter: Marijo Bilusic
Session: Poster Display session 3
Resources:
Abstract
3142 - Multicenter Phase I Trial of a DNA Vaccine Encoding the Androgen Receptor Ligand Binding Domain (pTVG-AR, MVI-118) in Patients with Metastatic Prostate Cancer
Presenter: Douglas McNeel
Session: Poster Display session 3
Resources:
Abstract
4327 - Impact of germline mutations in Homologous Recombination (HR) genes on the response to Radium-223 for metastatic castration resistant prostate cancer (mCRPC)
Presenter: Elena Castro
Session: Poster Display session 3
Resources:
Abstract
3600 - Serum biomarkers of bone metabolism in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with Radium-223 (Ra223): Results from a prospective multicentre study
Presenter: Nuria Romero Laorden
Session: Poster Display session 3
Resources:
Abstract
3742 - Prognostic value of tumor suppression genes (TP53, PTEN, Rb) in metastatic hormone sensitive prostate cancer
Presenter: Miguel Gonzalez Velez
Session: Poster Display session 3
Resources:
Abstract
2643 - Germline sequencing of advanced prostate cancer patients in the BARCODE2 trial
Presenter: Sarah Benafif
Session: Poster Display session 3
Resources:
Abstract
4349 - Impact of treatment sequence in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): data from the prospective PROREPAIR-B study.
Presenter: Carlo Cattrini
Session: Poster Display session 3
Resources:
Abstract
3301 - Implications of Single Nucleotide Polymorphisms (SNPs) in Androgen Related-Genes in Outcome of metastatic castration-resistant prostate cancer (mCRPC) patients treated with Abiraterone (Abi) and Enzalutamide (Enza)
Presenter: Isabel Aragon
Session: Poster Display session 3
Resources:
Abstract
2275 - Activating mutations in AKT1/PIK3CA are associated with poor clinical outcomes in metastatic prostate cancer (mPC)
Presenter: Simon Fu
Session: Poster Display session 3
Resources:
Abstract